Cue Biopharma (CUE) Total Debt (2022 - 2026)

Cue Biopharma has disclosed Total Debt across 5 years of filings, most recently posting $960000.0 for Q2 2026.

• In Q2 2026, Total Debt fell 63.16% year-over-year to $960000.0; the TTM figure through Jun 2026 stood at $960000.0 (down 63.16% YoY), while the FY2025 annual figure was $689000.0, down 84.1% from the prior year.
• Total Debt came in at $960000.0 for Q2 2026 at Cue Biopharma, up from $689000.0 in the prior quarter.
• In the past five years, Total Debt ranged from a high of $10.1 million in Q2 2023 to a low of $689000.0 in Q4 2025.
• Average Total Debt over 5 years is $6.5 million, with a median of $7.2 million recorded in 2024.
• Year-over-year, Total Debt rose 2.19% in 2023 and slumped 84.1% in 2025.
• Over 5 years, Total Debt stood at $10.0 million in 2022, then dropped by 18.33% to $8.2 million in 2023, then slumped by 46.93% to $4.3 million in 2024, then tumbled by 84.1% to $689000.0 in 2025, then soared by 39.33% to $960000.0 in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $960000.0 in Q2 2026, $689000.0 in Q4 2025, and $1.6 million in Q3 2025.